Does personalized medicine cut the mustard when it comes to treating cancer? Richard Smith, a former editor of the British Medical Journal, believes that it does not. Using the mustard metaphor, he shows how personalized medicine undermines the pharmaceutical industry’s profits. If the one-size-fits-all approach to prescribing cancer drugs were abandoned, drug companies would be forced to change their business model, most notably by increasing prices radically – or stop producing the drugs altogether.
View the original article here: Personalized Medicine’s Perverse Economics
Personalized medicine’s perverse economics
Donna Dickenson | Project Syndicate | December 21, 2012
{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}
Infographics | More... |
Are pesticide residues on food something to worry about?
In 1962, Rachel Carson’s Silent Spring drew attention to pesticides and their possible dangers to humans, birds, mammals and the ...
Most Popular
- Did you hear the story about the GMO that nearly destroyed the world?
- Coming era of cattle farming: Genetically engineered dairy cow produces human insulin in milk
- What is ‘carbon farming’ and could it provide a path to a more sustainable agricultural future?
- Studying chimpanzees illuminates how speech evolved in humans
- GLP podcast: GE crops have lived up to the hype; Growing ‘mini’ organs from stem cells; How do we solve right-wing vaccine hesitancy?
- The radical conservative case for genetic enhancement
- Is tilapia a human-made freak that we should avoid — or an evolutionary rockstar?
- Cheese: The GMO food die-hard GMO opponents love, but don’t want to label
- How Freddie Mercury got his voice: It wasn’t his teeth
- Golden Rice: The GMO crop loved by humanitarians, opposed by Greenpeace